Abstract：Objective To analyze the clinical efficacy of Kuntai Capsules combined with Dydrogesterone in the treatment of climacteric syndrome with anxiety and depression.Methods By a random number table,80 menopausal syndrome patients with anxiety and depression treated in our hospital from March 2015 to June 2016 were divided into control group and observation group.The control group was treated with Dydrogesterone and the observation group was treated Kuntai Capsules combined with Dydrogesterone respectively.The clinical therapeutic effect in the two groups were observed and compared.Results There was no significant difference in Kupperman(K)score,Hamilton Anxiety Rating Scale(HAMA)score or Hamilton Depression Scale(HAMD)score before treatment between the two groups(P＞0.05).After treatment,the K score was significantly higher in the observation group(P＜0.05).With regard to total effectiveness rate,the rate in the observation group was significantly higher compared with that in the control group(P＜0.05).After therapy,the HAMA and HAMD scores decreased significantly in the observation group in comparison with those in the control group,the differences were statistically significant(P＜0.05).Conclusion The combination of Kuntai Capsules and dydrogesterone for menopausal syndrome with anxiety and depression has a remarkable clinical effect on increasing K score,decreas HAMA and HAMD scores.
康幼红； 周宏. 坤泰胶囊联合地屈孕酮治疗更年期综合征伴焦虑抑郁的临床研究[J]. 中国当代医药, 2018, 25(13): 141-143.
KANG You-hong；ZHOU Hong. Clinical study of Kuntai Capsules combined with Dydrogesterone in the treatment of climacteric syndrome with anxiety and depression. 中国当代医药, 2018, 25(13): 141-143.
Namiki T，Sato H，Matsumoto Y，et al.Identification of a predictivebiomarkerforthebeneficialeffectofkeishibukuryogan，a kampo（Japanese traditional）medicine，on patients with climactericsyndrome[J].EvidBasedComplementAlternatMed，2014，2014：962109.
京公网安备 11010502046607号